News Quantified

EGRX – eagle pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.

Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration [Yahoo! Finance]

Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration

Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.

Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer

Form 3 EAGLE PHARMACEUTICALS, For: Nov 11 Filed by: Krawtschuk Christopher

Form 8-K EAGLE PHARMACEUTICALS, For: Nov 15

Form SC 13G/A EAGLE PHARMACEUTICALS, Filed by: BRANDES INVESTMENT PARTNERS, LP

Form SC 13G/A EAGLE PHARMACEUTICALS, Filed by: JANUS HENDERSON GROUP PLC

Form NT 10-Q EAGLE PHARMACEUTICALS, For: Sep 30

Top News Gainers

3/30 Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM® Rapid Infusion Liquid Bendamustine Formulation 12.9%

4/16 Eagle Pharmaceuticals Announces Laboratory Test Results Demonstrating In Vitro Antiviral Activity of RYANODEX® (dantrolene sodium) Against Coronavirus SARS-CoV-2 7.6%

5/7 Q1/2019 3/31/2019 EPS 1.010 ZacksConsensus 0.210 ActVsEst 0.800 - Beat 6.9%

3/2 Form 10-K EAGLE PHARMACEUTICALS, For: Dec 31 6.3%

3/17 Form 8-K EAGLE PHARMACEUTICALS, For: Mar 17 5.3%

12/10 Form 8-K EAGLE PHARMACEUTICALS, For: Dec 04 4.3%

6/4 Form 8-K EAGLE PHARMACEUTICALS, For: Jun 04 3.9%

8/8 Q2/2019 6/30/2019 EPS 0.840 ZacksConsensus 0.310 ActVsEst 0.530 - Beat 3.3%

7/3 Eagle Pharmaceuticals Inc (NASDAQ: EGRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $63.00 price target on the stock. 3.2%

1/13 Tyme Technologies: Why Investors Should Be Bullish On The Eagle Partnership [Seeking Alpha] 2.9%

Top News Decliners

4/28 Court Issues Favorable Patent Litigation Decision for Eagle Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd. for BENDEKA (bendamustine hydrochloride injection) -10.4%

3/6 Eagle Pharmaceuticals Inc (NASDAQ: EGRX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong sell" rating. -8.3%

3/2 Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Results -8.1%

4/21 Eagle Pharmaceuticals Inc (NASDAQ: EGRX) had its "hold" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $46.00 price target on the stock. -7.2%

3/16 Form 8-K EAGLE PHARMACEUTICALS, For: Mar 13 -6.0%

11/12 Form 8-K EAGLE PHARMACEUTICALS, For: Nov 12 -5.6%

4/29 Eagle Pharmaceuticals to Discuss First Quarter 2020 Financial Results on May 11, 2020 -5.1%

5/22 Form 8-K EAGLE PHARMACEUTICALS, For: May 22 -4.7%

1/7 Form 8-K EAGLE PHARMACEUTICALS, For: Jan 07 -4.4%

6/21 Form 8-K EAGLE PHARMACEUTICALS, For: Jun 21 -3.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day